T1	Participants 57 84	acute myelogenous leukemia.
T2	Participants 86 240	Twenty-seven patients receiving a standard cytosine arabinoside and daunorubicin regimen as induction of reinduction therapy of acute myelogenous leukemia
T3	Participants 324 409	Treatment groups were comparable with respect to age and baseline granulocyte counts.
